Result: For NNRTI resistance-associated mutations, V179D/T was identified as the major mutation (20 cases), and the other 6 types of mutation were E138A, A98G, K101P, K103 N, Y181H and Y188H.
Discussion: The major TDRMs observed in this study have been reported in a previous study of HIV Drug Resistance among ART-failure individuals in Yunnan Province, which figured out mutations such as M184 V/I, K103 N, V106A, Y181C and G190A were common.
Short Communication: Discordance in Drug Resistance Mutations Between Blood Plasma and Semen or Rectal Secretions Among Newly Diagnosed HIV-1-Infected Thai Men Who Have Sex with Men.
PMID: 29756454
2018
AIDS research and human retroviruses
Abstract: Three participants had DRAMs in anogenital compartments that were not detected in blood plasma-one had DRAMs in semen that was not detected in blood plasma (I54FI) and two had DRAMs in rectal secretions that was not detected in blood plasma (I47IM; K70N, L74I, Y115F, M184V, K103N, V108I, and H221Y).
Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study.
Abstract: The most common emergent RAMs to NRTIs were M184V/I (42.3%) and K65R (28.2%), and those to nNRTIs were Y181C (42.3%), K103N (15.5%), G190A/E/Q (12.7%),
Discussion: Apart from the common emergent RAMs observed in patients with first-line treatment failure in previous studies, such as M184V/I (42.3%), Y181C (42.3%), and K103N (15.5%), 28.2% of our patients with virological failure harbored K65R mutation, which was 6 times more likely to occur in those individuals receiving regimens containing TDF/FTC or TDF plus lamivudine and nevirapine.
[Study on the relationship between HIV drug resistance and CD4(+)T cell counts among antiretroviral therapy patients with low viral load].
PMID: 29973007
2018
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Abstract: The second one was K103N (NNRTI), and the percentage was 22.5% (50 cases).
Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.
PMID: 29977795
2018
African journal of laboratory medicine
Introduction: The most common non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations were K103N (58.1%), Y181C (41.9%) and G190A (6.5%), and the most frequent nucleoside reverse transcriptase inhibitor (NRTI) mutation was M184V (61.3%).
Discussion: In the present study, the K103N mutation was not detected from the mixed clone at 1% of minority variant level of control plasmids from 520 reads.
Discussion: Some minority K103N mutations could have been missed in this study.
Discussion: The H221Y mutation could also impact clinical outcomes as Y
Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: a retrospective analysis.
PMID: 30061964
2018
The Pan African medical journal
Abstract: They included K103N (n = 10), G190A (n = 1), Y181C (n = 1) and Y188L (n = 1).
Result: They included K103N (n=10), G190A (n=1), Y181C (n=1) and Y188L (n=1) (Table 2).
Table: K103N
Discussion: The most prevalent NNRTI mutation that was detected in the studied population was K103N, which is associated with the use of Nevirapine - also a major component of first line regimens in Kenya.
Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso.
PMID: 30079168
2018
Journal of public health in Africa
Result: K103N was detected more in children (11.1%) than in mothers but did not confer resistance to ARV used.
Discussion: (2015) where K103N was associated to resistance to NVP and EFV, in this study this mutation was not associated to any NNRTI.
Discussion: Some studies also found K103N and Y181C in individuals with subtypes A, B, C, F and CRF02_AG who developed resistance to NVP, ETR, and EFV.
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Introduction: One patient acquired virus with the Q148R mutation, conferring phenotypic resistance to RAL, EVG and CAB, in association with the K103N, E138G, and K238T, conferring cross-resistance to non-nucleoside RT inhibitors (NNRTIs).
Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
Abstract: The most common NRTI mutation found was M184 V; K103 N and A98G were the most common NNRTI mutations seen.
Discussion: K103 N and V106A are major mutations associated with
Discussion: For the mothers who were on ART after prophylaxis in the PMTCT programme, the HIV-1 drug resistance associated mutations seen were dominated by M184 V for NRTIs and Thymidine Analogue-Associated Mutations (TAMS) including M41 L and T215Y; and K103 N with A98G for NNRTIs.
HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013.
Result: Taken together, the G190A/S/E mutations were most prominent (seven of the 12 NNRTI mutations), followed by the K103N, Y181I/C and K101E substitutions (two, two and one, respectively).
Result: Two had K103N, one G190S and one Y181C, all representing resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI).
Discussion: The specific NNRTI associated mutations found in this study (K103N, G109S and Y181C) have been reported to account for the most
HIV mutation literature information.
PMID: 
2018
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT